Mark A. Morgan

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Medicine, Gynecology, Oncology +12

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Robert L. Coleman, Gini F. Fleming, Mark F. Brady et al. · New England Journal of Medicine · 2019 · 929 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Postprandial versus Preprandial Blood Glucose Monitoring in Women with Gestational Diabetes Mellitus Requiring Insulin Therapy

Margarita de Veciana, Carol Major, Mark A. Morgan et al. · New England Journal of Medicine · 1995 · 670 citations · Full text

Medicine, Endocrinology, Obstetrics +11

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of<i>BRCA1</i>

Stephen C. Rubin, Ivor Benjamin, Kian Behbakht et al. · New England Journal of Medicine · 1996 · 431 citations · Full text

Medicine, Oncology, Pathology +17

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

John Farley, William E. Brady, Vinod Vathipadiekal et al. · The Lancet Oncology · 2012 · 413 citations

Medicine, Oncology, Surgery +12